CJC-1295 + Ipamorelin Stack: Protocol, Dosing, Results, and What to Expect (2026 Guide)

Executive Summary

The CJC-1295 + Ipamorelin combination is the most widely prescribed growth hormone (GH) peptide stack in US telehealth clinics as of 2026. It is also one of the most commonly searched peptide topics — reflecting strong consumer interest in GH optimization for recovery, body composition, sleep quality, and anti-aging outcomes. The stack's popularity is grounded in pharmacology: CJC-1295 and Ipamorelin stimulate GH release through two distinct and complementary receptor pathways, producing a synergistic GH pulse that exceeds either peptide used alone.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor on anterior pituitary somatotrophs. In its DAC (Drug Affinity Complex) form, it has a prolonged half-life (~6–8 days) that maintains elevated baseline GH/IGF-1; in its no-DAC (mod GRF 1-29) form, it produces acute GH pulses with a shorter half-life (~30 minutes). Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist — one of the cleanest growth hormone-releasing peptides (GHRPs) available, with minimal effects on cortisol, prolactin, or appetite compared to older GHRPs like GHRP-6 or hexarelin.

When combined, CJC-1295 activates the GHRH pathway while Ipamorelin simultaneously activates the ghrelin pathway — resulting in a GH pulse that is both larger in amplitude and more physiologically patterned than either peptide alone. This guide covers the pharmacology of the stack, evidence-based dosing protocols, expected results timeline, side effects, cost, and how to select a provider. For individual peptide deep dives, see CJC-1295 dosage and protocol guide, ipamorelin vs CJC-1295 comparison, and sermorelin vs ipamorelin vs CJC-1295.

At-a-Glance Comparison

Standard dosing parameters for the CJC-1295 + Ipamorelin stack. Dosing reflects commonly prescribed telehealth protocols as of 2026. Individual dosing should be determined by a licensed provider.

Why Stack CJC-1295 and Ipamorelin? The Synergy Mechanism

The CJC-1295 + Ipamorelin stack is not simply two peptides used together for convenience. The combination activates two distinct GH-release pathways simultaneously, producing a synergistic effect that is pharmacologically well-characterized. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Pathway 1: GHRH receptor (CJC-1295). CJC-1295 binds the GHRH receptor on pituitary somatotrophs, directly stimulating GH synthesis and secretion. This is the same receptor activated by your body's endogenous GHRH. CJC-1295 effectively amplifies the GHRH signal — priming the somatotroph to release more GH when stimulated. Pathway 2: Ghrelin receptor / GHS-R1a (Ipamorelin). Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin. This pathway works through a different intracellular signaling cascade (IP3/DAG vs cAMP) than GHRH, which is why the two pathways are additive rather than redundant. Ipamorelin's selectivity for GHS-R1a (vs older GHRPs that also activate cortisol, prolactin, and appetite pathways) makes it the preferred GHRP for clinical stacking. The synergy: When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than either peptide alone — studies on GHRH + GHRP combinations consistently show 2–3× greater GH peak compared to either peptide individually. This synergy is not theoretical; it is reliably demonstrated in GH stimulation testing. The combination also produces a more natural pulsatile GH release pattern (vs sustained elevation from HGH injections), which may preserve hypothalamic-pituitary feedback more effectively. Why not just use HGH? Exogenous HGH provides a flat, non-pulsatile elevation in GH that bypasses pituitary function entirely. Over time, this suppresses endogenous GH production. The CJC-1295 + Ipamorelin stack stimulates your own pituitary to produce GH — maintaining pulsatility and (in theory) allowing pituitary function to recover after cessation. It is also significantly cheaper than pharmaceutical HGH and available through telehealth peptide clinics without the regulatory complexity of HGH prescribing. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The 2–3× GH amplification from dual-pathway stimulation is well-demonstrated in acute pharmacokinetic studies. However, whether this translates to proportionally greater clinical outcomes (recovery, body composition, sleep quality) over months of use has not been established in large controlled trials. Most clinical outcome data comes from observational clinic reports and patient self-reports, not RCTs. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

CJC-1295 + Ipamorelin Dosing Protocol: Standard and Advanced

Dosing the CJC-1295 + Ipamorelin stack requires understanding two key variables: which form of CJC-1295 you are using (no-DAC vs with-DAC), and your experience level with GH peptides. Most telehealth clinics prescribe the no-DAC (mod GRF 1-29) form paired with Ipamorelin. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Standard protocol (most common, recommended starting point): CJC-1295 no-DAC (mod GRF 1-29) 100 mcg + Ipamorelin 200 mcg — combined in the same syringe — injected subcutaneously once daily before bed. The before-bed timing leverages the natural nocturnal GH pulse and maximizes sleep-quality benefits. Injection should occur on an empty stomach (fasted ≥2 hours, ideally no carbs or fats for 2+ hours) because insulin and blood glucose blunt GH release. Enhanced protocol (after 4+ weeks of tolerance assessment): Some clinics escalate to twice-daily dosing — a morning fasted dose (CJC 100 mcg + Ipamorelin 200 mcg) and an evening pre-bed dose (same). This protocol is common in recovery-focused or body-composition-focused users. A third dose post-workout is sometimes added in aggressive protocols but increases cost and injection burden. CJC-1295 with DAC protocol (less common): If using CJC-1295 with DAC, the dosing schedule is different due to the 6–8 day half-life: 2,000 mcg (2 mg) injected once or twice per week. Ipamorelin is still dosed daily (200 mcg before bed). This hybrid approach provides sustained baseline GH elevation from DAC + acute pulsatile GH release from nightly Ipamorelin. Cycle structure: Most providers recommend 8–16 weeks on, followed by 4–8 weeks off to allow pituitary sensitivity to reset. Some clinics prescribe continuous use at lower doses (5 days on, 2 days off) — the evidence for whether cycling is necessary is limited, but the rationale is to prevent GH receptor desensitization. Reconstitution: Both peptides are supplied as lyophilized powder requiring reconstitution with bacteriostatic water. Standard reconstitution: add 2 mL bacteriostatic water to a 5 mg vial = 2,500 mcg/mL. Draw 0.04 mL (4 units on insulin syringe) = 100 mcg CJC-1295; draw 0.08 mL (8 units) = 200 mcg Ipamorelin. Store reconstituted peptides refrigerated (2–8°C); use within 28–30 days. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Dose escalation beyond the standard protocol increases cost and injection frequency without established proportional benefit in clinical outcomes. Starting at the standard dose for 4–8 weeks and assessing response (sleep quality, recovery, body composition trends) before escalating is the conservative and evidence-supported approach. Higher doses increase side effect risk (water retention, carpal tunnel symptoms, fasting glucose elevation). Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Expected Results Timeline: Weeks 1–24

Setting realistic expectations is critical for GH peptide therapy adherence. Unlike testosterone or GLP-1 agonists where blood markers change within weeks, GH peptide results are often subjective early on and measurable later. Here is what the clinical experience and patient-reported data consistently show. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Weeks 1–2: Most users report improved sleep quality within the first week — deeper sleep, more vivid dreams, feeling more rested on waking. This is the most consistent early-onset effect and is likely related to GH's role in slow-wave sleep promotion. Some users report mild water retention (1–3 lbs), tingling in fingers/toes, or increased appetite — these typically resolve within 2 weeks. Weeks 2–4: Recovery improvements become noticeable — faster recovery from exercise, reduced joint soreness, improved workout capacity. Skin quality changes may begin (increased hydration, improved elasticity). Energy and mood improvements are commonly reported. Weeks 4–8: Body composition changes become measurable — reductions in visceral and subcutaneous fat, particularly in the midsection, coupled with modest improvements in lean mass when combined with resistance training. Sleep quality improvements stabilize. Recovery benefits become consistent. Weeks 8–16: The primary body composition window. Fat loss and lean mass changes are most pronounced in this phase. Hair and nail growth improvements are reported by some users. IGF-1 levels, if tested, should show meaningful elevation (typically 30–80% increase from baseline, depending on dose and individual response). Weeks 16–24: Connective tissue and joint benefits may become noticeable — GH promotes collagen synthesis in tendons, ligaments, and cartilage, but these tissues remodel slowly. Cumulative anti-aging and skin benefits continue to improve. What the stack does NOT do: CJC-1295 + Ipamorelin will not produce HGH-level body composition transformations. The GH elevation is meaningful but modest compared to pharmaceutical HGH doses. Expect subtle, progressive improvements — not dramatic transformation. Users who expect HGH-like results are consistently disappointed. The stack works best as an optimization tool in the context of quality training, nutrition, and sleep — not as a substitute for those foundations. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Results timelines are based on clinical observation and patient reports, not controlled trials with placebo groups. Significant placebo effects are possible, particularly for subjective outcomes like sleep quality, energy, and recovery. Body composition changes are real but modest compared to pharmaceutical HGH and require concurrent resistance training and caloric management to be clinically meaningful. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Side Effects and Safety Profile

The CJC-1295 + Ipamorelin stack has one of the most favorable safety profiles among GH peptide combinations — largely because Ipamorelin's selectivity avoids the cortisol, prolactin, and appetite side effects of older GHRPs. Side effects are generally dose-dependent and manageable. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Common (>10% of users): Mild water retention (1–5 lbs, particularly in the first 2–4 weeks) — this is GH-mediated sodium retention and typically resolves or stabilizes. Injection site reactions (redness, mild swelling) — standard for subcutaneous peptide injections. Tingling or numbness in extremities (fingers, toes) — often transient, related to fluid shifts; if persistent, reduce dose. Uncommon (1–10%): Headache (usually mild, resolves within first 2 weeks). Flushing immediately post-injection (more common with Ipamorelin). Increased hunger (milder than GHRP-6 or hexarelin due to Ipamorelin's selectivity, but ghrelin pathway activation can increase appetite in some individuals). Joint stiffness (paradoxically, GH can cause joint stiffness in the short term before connective tissue remodeling improves joint health). Rare / dose-dependent (<1%): Carpal tunnel-like symptoms (wrist pain, hand numbness) — a classic sign of excessive GH elevation; reduce dose immediately if this occurs. Fasting glucose elevation — GH has anti-insulin effects; prolonged high-dose use can impair glucose tolerance, particularly in individuals with pre-existing insulin resistance. What Ipamorelin does NOT cause (vs other GHRPs): Unlike GHRP-6, Ipamorelin does not cause significant hunger spikes. Unlike GHRP-2 and hexarelin, it does not elevate cortisol or prolactin at therapeutic doses. This selectivity is the primary reason Ipamorelin is preferred for long-term stacking. Monitoring: Baseline and 8-week labs should include IGF-1 (target: age-appropriate upper-normal range, not supraphysiological), fasting glucose and insulin (to screen for GH-mediated insulin resistance), and comprehensive metabolic panel. If IGF-1 exceeds the upper reference range, dose reduction is indicated. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Long-term safety data (>2 years) on CJC-1295 + Ipamorelin are limited. The theoretical concern with sustained GH/IGF-1 elevation is cancer risk — IGF-1 is a mitogen and elevated levels are epidemiologically associated with increased cancer risk. Keeping IGF-1 in the upper-normal (not supraphysiological) range and cycling protocols are the standard mitigation strategies. Men with a personal or strong family history of cancer should discuss this risk with their provider before initiating GH peptide therapy. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Cost Breakdown and Provider Selection

The CJC-1295 + Ipamorelin stack is one of the most affordable GH peptide options — significantly cheaper than pharmaceutical HGH — but costs vary widely by provider, dosing protocol, and whether telehealth consultation and labs are included. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Peptide cost (medication only): CJC-1295 no-DAC: $40–80/vial (5 mg, ~50 doses at 100 mcg). Ipamorelin: $40–70/vial (5 mg, ~25 doses at 200 mcg). At standard once-daily dosing, expect roughly $80–$150/month for both peptides from a compounding pharmacy. Full-service telehealth cost: Most telehealth peptide clinics charge $200–$400/month for the CJC-1295 + Ipamorelin program, which typically includes: physician consultation, peptides, supplies (syringes, bacteriostatic water), and sometimes baseline lab work. Lab work may be additional ($100–$300 for initial panel). Comparison to alternatives: Pharmaceutical HGH (Norditropin, Genotropin) costs $800–$2,000+/month at therapeutic doses — 4–10× more expensive. Sermorelin (another GHRH analog) costs $150–$300/month through telehealth — comparable but uses only one GH pathway vs the dual-pathway stack. Tesamorelin is $500–$1,500+/month (FDA-approved, more expensive). Provider selection criteria: Look for clinics that require baseline labs before prescribing (including IGF-1, metabolic panel), provide clear dosing protocols with written instructions, offer follow-up labs at 8–12 weeks, have licensed providers who adjust dosing based on IGF-1 response, and use verified US compounding pharmacies (503B preferred). Red flags: clinics that prescribe without labs, do not offer follow-up monitoring, or source peptides from unverified suppliers. For provider comparisons, see best peptide clinics online 2026 and our provider comparison tool. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Peptide quality varies significantly between sources. Compounding pharmacies regulated under Section 503B of the FD&C Act are the highest-quality source — they operate under FDA oversight with cGMP requirements. 503A pharmacies (patient-specific compounding) are also legitimate but less rigorously inspected. Gray-market or research-chemical peptide suppliers carry unknown purity and contamination risks. Always verify that your provider sources from a licensed US compounding pharmacy. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How CJC-1295 + Ipamorelin Compares to Other GH Peptide Options

Several GH peptide options are available through telehealth clinics. Understanding how the CJC-1295 + Ipamorelin stack compares to alternatives helps patients and providers make informed protocol decisions. Buyers searching for cjc-1295 ipamorelin stack usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

vs Sermorelin alone: Sermorelin is a GHRH analog (29-amino acid fragment) that works through the same GHRH receptor as CJC-1295 — but has a much shorter half-life (~10–20 minutes vs ~30 min for CJC-1295 no-DAC). Sermorelin alone produces a smaller GH pulse than the CJC-1295 + Ipamorelin dual-pathway combination. Sermorelin is sometimes preferred for GH peptide beginners due to its long safety record. For a detailed comparison, see sermorelin vs ipamorelin vs CJC-1295. vs Tesamorelin: Tesamorelin is an FDA-approved GHRH analog (for HIV-associated lipodystrophy) with stronger clinical evidence than any other GH peptide. It produces robust GH elevation and has proven visceral fat reduction in RCTs. Tesamorelin is significantly more expensive ($500–$1,500+/month). For details, see tesamorelin peptide guide. vs Hexarelin: Hexarelin is a potent GHRP that produces the strongest acute GH pulse among available GHRPs — but also elevates cortisol and prolactin, and shows rapid desensitization with repeated dosing. Ipamorelin's clean selectivity profile makes it preferred for long-term use. See hexarelin guide. vs MK-677 (Ibutamoren): MK-677 is an oral ghrelin receptor agonist — same pathway as Ipamorelin but taken by mouth. Advantages: no injections. Disadvantages: 24-hour half-life means sustained (non-pulsatile) GH/IGF-1 elevation; significant appetite increase; water retention; potential insulin resistance with chronic use. MK-677 is not a peptide (it is a non-peptide GH secretagogue). vs Pharmaceutical HGH: HGH provides the most potent and predictable GH elevation but at 4–10× the cost, with loss of pulsatility, pituitary suppression, and more regulatory complexity. The CJC-1295 + Ipamorelin stack is the most commonly chosen alternative for patients who want GH optimization without HGH's cost and regulatory burden. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Head-to-head clinical trials comparing CJC-1295 + Ipamorelin to sermorelin, tesamorelin, or HGH for specific clinical outcomes (recovery, body composition, sleep) do not exist. Comparisons are based on pharmacokinetic data (GH pulse magnitude, selectivity profiles) and clinical observation. Individual response varies significantly. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you are considering the CJC-1295 + Ipamorelin stack, the right first step is a provider consultation with baseline labs — including IGF-1 and a metabolic panel. Our provider comparison tool helps you find clinics that include labs, clear protocols, and follow-up monitoring — the non-negotiable elements of responsible GH peptide therapy.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the CJC-1295 + Ipamorelin stack?

It is a combination of two peptides that stimulate growth hormone release through complementary pathways. CJC-1295 activates the GHRH receptor and Ipamorelin activates the ghrelin receptor — together they produce a synergistic GH pulse that is 2–3× larger than either peptide alone. It is the most commonly prescribed GH peptide combination in US telehealth clinics.

How much does the CJC-1295 + Ipamorelin stack cost?

Peptide-only cost is roughly $80–$150/month at standard once-daily dosing. Full-service telehealth programs (consultation, peptides, supplies, monitoring) typically cost $200–$400/month. This is significantly cheaper than pharmaceutical HGH ($800–$2,000+/month).

How long does it take to see results from CJC-1295 + Ipamorelin?

Sleep quality improvements are often reported within the first 1–2 weeks. Recovery benefits at 2–4 weeks. Measurable body composition changes (fat loss, lean mass improvements) typically emerge at 4–8 weeks and peak at 8–16 weeks. Connective tissue and joint benefits may take 16–24 weeks. Results require concurrent resistance training and nutrition optimization.

What is the best time to inject CJC-1295 + Ipamorelin?

Before bed on an empty stomach (fasted ≥2 hours) is the standard and most recommended timing. This leverages the natural nocturnal GH pulse and maximizes sleep-quality benefits. Some protocols add a morning fasted dose for enhanced effect. Avoid injecting after meals — insulin and blood glucose blunt GH release.

Can I mix CJC-1295 and Ipamorelin in the same syringe?

Yes — most clinics instruct patients to draw both peptides into the same insulin syringe and inject together. This is standard practice and does not affect efficacy. Some patients prefer separate injections but there is no pharmacological reason to do so.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (also called mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses similar to natural physiology. CJC-1295 with DAC has a half-life of ~6–8 days due to albumin binding, producing sustained GH/IGF-1 elevation. Most telehealth clinics prescribe the no-DAC form for stacking with Ipamorelin because it maintains pulsatile release patterns.

Do I need to cycle CJC-1295 + Ipamorelin?

Most providers recommend 8–16 weeks on, 4–8 weeks off to allow pituitary sensitivity to reset and prevent GH receptor desensitization. Some clinics prescribe continuous use at lower doses with periodic off-days (5 on / 2 off). The evidence for optimal cycling structure is limited — follow your provider's protocol.

Is CJC-1295 + Ipamorelin safer than HGH?

The stack has a favorable safety profile at therapeutic doses — it maintains pulsatile GH physiology (vs HGH's flat elevation), preserves pituitary function, and Ipamorelin's selectivity avoids cortisol/prolactin elevation. However, long-term safety data (>2 years) are more limited than for pharmaceutical HGH. Both require monitoring of IGF-1 and metabolic markers.

What side effects should I watch for?

Common: mild water retention (1–5 lbs, usually first 2–4 weeks), injection site reactions, tingling in fingers/toes. Uncommon: headache, flushing. Red flags requiring dose reduction: carpal tunnel symptoms (wrist pain, hand numbness), persistent elevated fasting glucose. Contact your provider if these occur.

Where can I get CJC-1295 + Ipamorelin prescribed?

The stack is available through licensed telehealth peptide clinics that prescribe from US compounding pharmacies. Look for clinics requiring baseline IGF-1 and metabolic labs, providing written dosing protocols, and offering follow-up monitoring at 8–12 weeks. See our best peptide clinics 2026 guide and provider comparison tool.